Fox Run Management, L.L.C. Aldeyra Therapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $608 Million
- Q1 2025
A detailed history of Fox Run Management, L.L.C. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 22,912 shares of ALDX stock, worth $59,112. This represents 0.02% of its overall portfolio holdings.
Number of Shares
22,912Holding current value
$59,112% of portfolio
0.02%Shares
5 transactions
Others Institutions Holding ALDX
# of Institutions
139Shares Held
38.6MCall Options Held
620KPut Options Held
435K-
Perceptive Advisors LLC New York, NY9.28MShares$23.9 Million2.23% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$14.1 Million21.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.72MShares$9.59 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$9.34 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.75MShares$4.52 Million2.26% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $150M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...